Nexgenix Pharmaceuticals, Inc.

Universitéde Strasbourg

Bio-thera Solutions, Ltd., Co.

Bio-thera Solutions, Ltd.

Oncosynergy, Inc.

Jin-Chen Yu

John C Chabala

Ruihong Chen

Allan E Rubenstein

Shengfeng Li

Weijia Tang

Scott Stewart

Xiaodong Shen

Nicolas Winssinger

Sofia Barluenga

Chao Qin

Xiaobin Deng

Ziqiang Ou

Yili Yang

Xian Peng

Xiaoyang Huang

Marco Giovannini

James Heck

Allan Rubenstein

The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.

Compounds and methods for the treatment of TROP2 positive diseases

Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

Compounds and methods for the treatment of ERB B2/NEU positive diseases

A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.

Local treatment of neurofibromas

The present invention provides compounds of formulae Ia, Ia', IIa, IIa&#x2032;, IIIa, IIIa&#x2032;, IVa, or Va and the therapeutic use thereof. The present invention also includes methods of treating NF2-deficient or NF1-deficient cells or neurodegenerative diseases with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia&#x2032;, IIa, IIa&#x2032;, IIIa, IIIa&#x2032;, IVa, or Va. Furthermore, the present invention is directed to methods of inhibiting the growth of NF2-deficient or NF1-deficient tumors. The methods comprise contacting NF2-deficient or NF1-deficient tumor cells with radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia&#x2032;, IIa, IIa&#x2032;, IIIa, IIIa&#x2032;, IVa, or Va. The present invention is also directed to the combinational use of radicicol or its derivatives, such as one or more compounds of formula I, II, III, IV, V, Ia, Ia&#x2032;, IIa, IIa&#x2032;, IIIa, IIIa&#x2032;, IVa, or Va with at least one additional active agent, such as one or more HSP90 inhibitors.

Treatment of neurofibromatosis with radicicol and its derivatives

Growing community of inventors

Palo Alto, CA, United States of America

Jin-Chen Yu